| [1] |
《蕈样肉芽肿治疗中国专家共识(2023)》编写专家组, 沈小雁, 郑捷. 蕈样肉芽肿治疗中国专家共识(2023)[J]. 中华皮肤科杂志, 2023, 56(5): 402-409. DOI: 10.35541/cjd.20220909.
|
| [2] |
Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome-update 2023[J]. Eur J Cancer, 2023, 195: 113343. DOI: 10.1016/j.ejca.2023.113343.
|
| [3] |
Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J]. Lancet, 2017, 390(10094): 555-566. DOI: 10.1016/S0140-6736(17)31266-7.
pmid: 28600132
|
| [4] |
Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis[J]. Eur J Cancer, 2021, 148: 411-421. DOI: 10.1016/j.ejca.2021.01.054.
pmid: 33794441
|
| [5] |
国家癌症中心/国家肿瘤质控中心. 蕈样霉菌病全身皮肤放射治疗临床指南[J]. 中华放射肿瘤学杂志, 2024, 33(8): 687-697. DOI: 10.3760/cma.j.cn113030-20230602-00154.
|
| [6] |
中国临床肿瘤学会(CSCO)淋巴瘤专家委员会. 常见原发性皮肤T细胞淋巴瘤诊疗中国专家共识(2024年版)[J]. 白血病·淋巴瘤, 2024, 33(6): 321-328. DOI: 10.3760/cma.j.cn115356-20240520-00067.
|
| [7] |
Photiou L, van der Weyden C, McCormack C, et al. Systemic treatment options for advanced-stage mycosis fungoides and Sézary syndrome[J]. Curr Oncol Rep, 2018, 20(4): 32. DOI: 10.1007/s11912-018-0678-x.
|
| [8] |
Ribereau-Gayon E, Donzel M, Pham F, et al. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas[J]. Leuk Lymphoma, 2023, 64(8): 1424-1432. DOI: 10.1080/10428194.2023.2216820.
|
| [9] |
Torre‐Castro J, Recio‐Monescillo M, Castillo Bazan E, et al. Safety and effectiveness of the combination of systemic gemcitabine and intralesional brentuximab vedotin in tumor-stage mycosis fungoides[J]. Int J Dermatol, 2024, 63(6): 828-830. DOI: 10.1111/ijd.17107.
|
| [10] |
Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J]. Ann Oncol, 2015, 26(8): 1766-1771. DOI: 10.1093/annonc/mdv237.
pmid: 26105599
|
| [11] |
Zhang N, Zhang S, Ma L, et al. Case report: successful treatment of chidamide in a refractory/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT[J]. Medicine (Baltimore), 2023, 102(40): e35413. DOI: 10.1097/MD.0000000000035413.
|
| [12] |
魏冲, 张炎, 张薇, 等. 西达本胺联合PD-1单抗治疗Sézary综合征获得持续缓解1例[J]. 中华血液学杂志, 2022, 43(2): 165. DOI: 10.3760/cma.j.issn.0253-2727.2022.02.016.
|
